These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 24630437)

  • 1. Assessment of home infusion program for treating nonlaryngeal hereditary angioedema attacks.
    Kuhlen J; Guyer A; Morphew T; Tachdjian R; Banerji A
    Ann Allergy Asthma Immunol; 2014 May; 112(5):471-2. PubMed ID: 24630437
    [No Abstract]   [Full Text] [Related]  

  • 2. Ecallantide for the treatment of acute attacks in hereditary angioedema.
    Cicardi M; Levy RJ; McNeil DL; Li HH; Sheffer AL; Campion M; Horn PT; Pullman WE
    N Engl J Med; 2010 Aug; 363(6):523-31. PubMed ID: 20818887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response time for ecallantide treatment of acute hereditary angioedema attacks.
    Riedl M; Campion M; Horn PT; Pullman WE
    Ann Allergy Asthma Immunol; 2010 Dec; 105(6):430-436.e2. PubMed ID: 21130380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA approves kallikrein inhibitor to treat hereditary angioedema.
    Thompson CA
    Am J Health Syst Pharm; 2010 Jan; 67(2):93. PubMed ID: 20065259
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of ecallantide in pediatric hereditary angioedema.
    MacGinnitie AJ; Davis-Lorton M; Stolz LE; Tachdjian R
    Pediatrics; 2013 Aug; 132(2):e490-7. PubMed ID: 23878046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current characteristics associated with hereditary angioedema attacks and treatment: the home infusion based patient experience.
    Tachdjian R; Banerji A; Guyer A; Morphew T
    Allergy Asthma Proc; 2015; 36(2):151-9. PubMed ID: 25715244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema.
    Bernstein JA; Shea EP; Koester J; Iarrobino R; Pullman WE
    Allergy; 2012 Sep; 67(9):1173-80. PubMed ID: 22765833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful use of ecallantide to treat a hereditary angioedema attack after failure of C1 inhibitor prophylaxis.
    Burke S; Petrov A; Johnson J; MacGinnitie A
    Ann Allergy Asthma Immunol; 2011 Aug; 107(2):181-2. PubMed ID: 21802029
    [No Abstract]   [Full Text] [Related]  

  • 9. Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks.
    Craig TJ; Li HH; Riedl M; Bernstein JA; Lumry WR; MacGinnitie AJ; Stolz LE; Biedenkapp J; Chyung Y
    J Allergy Clin Immunol Pract; 2015; 3(2):206-212.e4. PubMed ID: 25609335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies.
    Sheffer AL; Campion M; Levy RJ; Li HH; Horn PT; Pullman WE
    J Allergy Clin Immunol; 2011 Jul; 128(1):153-159.e4. PubMed ID: 21481442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hereditary angioedema therapies in the United States: movement toward an international treatment consensus.
    Riedl M
    Clin Ther; 2012 Mar; 34(3):623-30. PubMed ID: 22386830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability.
    Bernstein JA; Qazi M
    Expert Rev Clin Immunol; 2010 Jan; 6(1):29-39. PubMed ID: 20383888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three new drugs for hereditary angioedema.
    Med Lett Drugs Ther; 2010 Aug; 52(1345):66-7. PubMed ID: 20724964
    [No Abstract]   [Full Text] [Related]  

  • 14. Recent advances in the management of hereditary angioedema.
    Hemperly SE; Agarwal NS; Xu YY; Zhi YX; Craig TJ
    J Am Osteopath Assoc; 2013 Jul; 113(7):546-55. PubMed ID: 23843378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Home treatment of hereditary angioedema with icatibant administered by health care professionals.
    Farkas H; Csuka D; Zotter Z; Varga L; Böröcz Z; Temesszentandrási G; Jakab L; Karádi I
    J Allergy Clin Immunol; 2012 Mar; 129(3):851-852.e2. PubMed ID: 22154383
    [No Abstract]   [Full Text] [Related]  

  • 16. The therapeutic landscape for hereditary angioedema: more change on the horizon?
    Riedl MA
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):337-8. PubMed ID: 25256026
    [No Abstract]   [Full Text] [Related]  

  • 17. Infusion techniques for perinatal home care.
    Eaton DG
    Caring; 1995 May; 14(5):40-2. PubMed ID: 10142352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.
    Gandhi PK; Gentry WM; Bottorff MB
    Pharmacotherapy; 2012 Oct; 32(10):902-9. PubMed ID: 23033229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management and prevention of hereditary angioedema attacks.
    Lumry WR
    Am J Manag Care; 2013 Jun; 19(7 Suppl):s111-8. PubMed ID: 23844783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful resolution of bowel obstruction in a patient with hereditary angioedema.
    Zingale LC; Zanichelli A; Deliliers DL; Rondonotti E; De Franchis R; Cicardi M
    Eur J Gastroenterol Hepatol; 2008 Jun; 20(6):583-7. PubMed ID: 18467921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.